|
Published by: Business Monitor International
Published: Aug. 18, 2008 - 62 Pages
Table of Contents
- Executive Summary
- Kazakhstan Pharmaceuticals And Healthcare SWOT
- Kazakhstan Political SWOT
- Kazakhstan Economic SWOT
- Kazakhstan - Business Environment Ranking
- Table: Central And Eastern Europe Pharmaceutical And Healthcare Business Environment Rankings
- Limits Of Potential Returns
- Risks To Realisation Of Returns
- Kazakhstan - Market Summary
- Regulatory Regime
- Intellectual Property Environment
- Counterfeit Drugs
- Pricing and Reimbursement Regime
- Table: Price Components And Add-ons For Imported And Locally Produced Generic Medicines (KZT)
- Recent Pricing And Reimbursement Developments
- Industry Developments
- Epidemiology
- Healthcare Sector
- Table Top 10 Manufacturers By Value Of Hospital Purch 18
- Table Top 10 INNs By Value Of Hospital Purchases
- Healthcare Sector Financing
- Table: Top 10 ATC Groups By Value Of Hospital Purchas 20
- Table: Top 10 ATC Groups By Retail Pharmacy Sales
- Domestic Pharmaceutical Industry
- Recent Domestic Industry Developments
- Wholesale And Retail
- Recent Wholesale And Retail Developments
- Foreign Pharmaceutical Industry
- Table: Indo-Kazakh Trade Figures (US$mn)
- Recent Foreign Industry Developments
- Table: Pharmaniaga Key Products
- Medical Devices
- Table Medical Devices Market In Kazakhstan (US$mn)
- Industry Forecast Scenario
- Overall Market Forecast
- Table: Kazakhstan - Drug Expenditure And Prescription Market Indicators
- Key Growth Factors - Industry
- Table: Kazakhstan Health Expenditure Forecast Indicators
- Key Growth Factors - Macroeconomic
- Table: Economic Activity
- Patented Market Forecast
- Table: Kazakhstan’s Patented Drug Market Indicators (US$’000 unless otherwise stated)
- Generics Market Forecast
- Table: Kazakhstan’s Generics Market Forecast Indicators. 37
- OTC Market Forecast
- Table: Kazakhstan OTC Market Forecast Indicators (US$’000 unless otherwise stated)
- Export/Import Market Forecasts
- Table: Trade Figures (US$mn)
- Table Retail Sales Structure Of Imports By Pharmaceutical Subgroups, 2006
- Table: Top 15 Distributors By Value Importing Pharmaceuticals Into Kazakhstan, 2006
- Table: Top 15 Distributors By Volume Importing Pharmaceuticals Into Kazakhstan, 2006
- Other Healthcare Data Forecasts
- Table: Other Healthcare Data
- Key Risks To BMI’s Forecast Scenario
- Competitive Landscape
- Table Top Ten Manufacturers by Retail Pharmacy Sales
- Top Ten Trade Names by Value of Retail Pharmacy Sales .. 47
- Company Monitor
- Foreign Companies
- Novartis (Sandoz)
- Sanofi-Aventis
- GlaxoSmithKline (GSK)
- Nycomed
- Merck & Co
- Pfizer
- Ranbaxy
- Indigenous Companies
- Chimpharm
- Romat FK
- BMI Forecast Modelling
- How We Generate Our Pharmaceutical Industry Forecasts
- Pharmaceutical Industry
- Pharmaceutical Business Environment Ratings Methodology .. 59
- Ratings Overview
- Table: Pharmaceutical Business Environment Indicators
- Weighting
- Table: Weighting Of Components
- Sources
AbstractKazakhstan’s pharmaceutical and healthcare markets have developed strongly over the past decade, driven by economic improvements. In fact, Kazakhstan's President recently claimed that the country's health expenditure had increased 12-fold since the country gained independence in 1991. Indeed, economic prosperity has allowed greater investment in the health infrastructure, with around 4,000 healthcare units of varying scope being built in rural areas over the past few years. In the meantime, 350 large medical centres have been constructed across the country, while work on 56 hospitals and 83 outpatient hospitals has began in 2008.
By 2012, BMI expects the market to be worth around US$1.645bn, growing at a CAGR of some 20% in the forecast period. BMI expects the economy to grow by around 8% in 2008, with the trend also benefiting healthcare and pharmaceutical expenditure. More specifically, the government is planning to raise the amount of GDP spent on healthcare to 3.7% in 2008. In 2004, only 3.5% of GDP was spent on health. Given the predicted GDP increase, the absolute difference in healthcare funding is likely to be substantial.
However, modernisation and expansion of healthcare and pharmaceutical access will come at a price. Consequently, in June 2008, in an effort to lower state expenditure on pharmaceuticals, Kazakhstan's Ministry of Health announced the creation of a new centralised system for drug distribution, which will cover between 70-80% of hospital drugs. More specifically, a single company-concessionaire, formed through a public-private partnership, will be chosen to procure and supply medicines to state organisations through a three-year renewable contract. The system will supply medicines to hospitals at lower prices, due to centralised bulk purchasing, allowing extra resources to be allocated to expanding the scope free health services in the country.
Finally, in the BMI Business Environment Ranking matrix for Q308, Kazakhstan is once again ranked 15th (above only Serbia) out of the 17 regional markets surveyed in CEE, now that Turkey has been included in this Emerging Europe region. In this quarter, Kazakhstan shares the position with Ukraine, as in Q108. While enjoying a considerable level of political and economic stability, the country is marked down for absolute market value and per capita consumption of medicines, as well as the lack of universal reimbursement and plans to introduce a fixed average price for outpatient medicines.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2008
|
